arrow
R

Ryuji Uozumi

Institute of Science Tokyo
H指数:26
被引数:2,486

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trial

类风湿关节炎患者靶向药物治疗减量期间个性化运动疗法的疗效:一项试点随机对照试验

2026-05-130
PRE
Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study

益生菌与接受质子泵抑制剂治疗的食管癌患者使用纳武利尤单抗或帕博利珠单抗有效性的关联:一项多中心回顾性研究

2026-05-011
PRE
Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer

免疫相关不良事件与接受免疫检查点抑制剂联合化疗治疗的肺癌患者生存期的关联

2026-04-030
OAAI
Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study
2023-01-012
OAAI
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
2022-12-279
OAAI
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
2022-11-0118
OAAI
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study
2022-04-2117
OAAI
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis
2022-03-233
OAAI